About Galleon Pharmaceuticals
Galleon Pharmaceuticals has built a drug discovery and development platform that focuses on the pharmaceutical treatment of sleep apnea and related breathing-control disorders. The company's platform incorporates recent advances in neurobiology, molecular physiology, respiratory medicine and medicinal chemistry. The Company has developed proprietary models of sleep apnea and breathing control that enable a multi-dimensional analysis of the primary causes of sleep apnea and related conditions.
Missing: Galleon Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Galleon Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Galleon Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Galleon Pharmaceuticals is included in 2 Expert Collections, including Sleep Health & Wellness.
Sleep Health & Wellness
These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.
Galleon Pharmaceuticals Patents
Galleon Pharmaceuticals has filed 8 patents.
Sleep disorders, Trifluoromethyl compounds, Abnormal respiration, Designer drugs, Respiratory therapy
Sleep disorders, Trifluoromethyl compounds, Abnormal respiration, Designer drugs, Respiratory therapy
Latest Galleon Pharmaceuticals News
Jan 11, 2017
Galleon Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 15:18 EST 11 Jan 2017 | BioPortfolio Reports Home » Topics » Sleep Disorders » Latest News » Galleon Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 Summary Galleon Pharmaceuticals Inc Galleon is a pharmaceutical company that discovers, develops and markets sleep apnea and related breathing control products. The company develops GAL021, GLN 21,160, and GAL044 products. It's GAL021 is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea. Galleon's GLN 21,160 is an oral development candidate for sleep apnea. The company serves patients with breathing related symptoms, such as decreased respiratory drive, elevated carbon dioxide, oxygen desaturations, breathing instability and both central and obstructive apneas. Galleon is headquartered in Horsham, Pennsylvania, the US. Galleon Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Galleon Pharmaceuticals Frequently Asked Questions (FAQ)
When was Galleon Pharmaceuticals founded?
Galleon Pharmaceuticals was founded in 2005.
Where is Galleon Pharmaceuticals's headquarters?
Galleon Pharmaceuticals's headquarters is located at 213 Witmer Road, Horsham.
What is Galleon Pharmaceuticals's latest funding round?
Galleon Pharmaceuticals's latest funding round is Series B.
How much did Galleon Pharmaceuticals raise?
Galleon Pharmaceuticals raised a total of $16.5M.
Who are the investors of Galleon Pharmaceuticals?
Investors of Galleon Pharmaceuticals include Morgenthaler Ventures, TPG Biotech and BioAdvance.
Who are Galleon Pharmaceuticals's competitors?
Competitors of Galleon Pharmaceuticals include ISA Pharmaceuticals, Constellation Pharmaceuticals, Anacor Pharmaceuticals, Catabasis Pharmaceuticals, Ikaria and 10 more.
Compare Galleon Pharmaceuticals to Competitors
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.
Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.
United Biomedical operates as a biopharmaceutical company. The Company develops immunotherapeutics and vaccines for chronic and infectious diseases.
Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases
Occam BioLabs is a company engaged in developing technologies for detection and quantification of biomolecules. The company is focused on three general areas of research and development: design and prototyping of electro-optical devices for analysis of biological samples, developing analytic reagents and kits for emergent biomedical fields, providing expertise services for assay optimization including high-throughput quantification in the pharmaceutical industry.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.